 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LB1909 / Legend Biotech
Enrollment change, Trial completion date, Trial termination: A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Nov 1, 2021
P1, N=1, Terminated, Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
N=28 --> 1 | Trial completion date: May 2023 --> May 2021 | Recruiting --> Terminated; Suitable patients were not recruited
- | LB1909 / Legend Biotech
Trial primary completion date: A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Dec 9, 2020
P1, N=28, Recruiting, Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
N=28 --> 1 | Trial completion date: May 2023 --> May 2021 | Recruiting --> Terminated; Suitable patients were not recruited Trial primary completion date: May 2023 --> May 2021
- | LB1909 / Legend Biotech
Enrollment change, Trial withdrawal, CAR T-Cell Therapy: Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 5, 2020
P1, N=0, Withdrawn, Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
Trial primary completion date: May 2023 --> May 2021 N=30 --> 0 | Recruiting --> Withdrawn
- | LB1909 / Legend Biotech
New P1 trial, CAR T-Cell Therapy: Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 18, 2019
P1, N=30, Recruiting, Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
- | LB1909 / Legend Biotech
Trial initiation date: A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Feb 15, 2019
P1, N=9, Recruiting, Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
N=30 --> 0 | Recruiting --> Withdrawn Initiation date: Sep 2018 --> Feb 2019
- | LB1909 / Legend Biotech
New P1 trial: A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Jul 18, 2018
P1, N=12, Recruiting, Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University